Phiphen Group Showcases at J.P. Morgan Healthcare Conference: Advancing Precision Diagnostics Through Life Science Innovation

Pacific Time2023YearMorning of January 11, Chief Financial Officer of Fapon Group (CFO) and Chief Investment Officer (CIO)Mr. Zhu Jielun at the41The J.P. Morgan Healthcare Conference (Delivered a keynote address at the J.P. Morgan Healthcare Conference, sharingCompletedFapon GroupThe Development Journey in the Field of Life Sciences,Series of Achievementsand future plans, interpreting how Fapon Group is extending its upstream life sciences foundational technological advantages from in vitro diagnostics to pharmaceuticals/Research Field，and empower global partners on the ecosystem platform to achieve symbiotic growth and shared prosperityseries of measures.

Currently, Fapon Group focuses on three core business areas: reagent raw material solutions, platform ecosystem services, and intelligent digital diagnostics. It has established a global R&D, manufacturing, marketing, and service network, with products exported to 61 countries and regions worldwide and serving over 1,500 global customer partners. Mr. Zhu Jielun currently serves as Chief Financial Officer (CFO) and Chief Investment Officer (CIO) of Fapon Group, with overall responsibility for formulating and implementing the group’s capital strategy, overseeing mergers and acquisitions, and managing post-investment activities. With more than 16 years of experience spanning investment banking and strategic consulting, Mr. Zhu is a leading capital expert in the life sciences and healthcare industries.

As a leading financial institution in the global pharmaceutical and biotechnology industry, JPMorgan Chase hosts the prestigious JPMorgan Healthcare Conference annually. Reportedly, this year’s conference attracted approximately 8,000 attendees, with representatives from prominent healthcare institutions, investors, entrepreneurs, non-profit organizations, and service providers gathering in San Francisco, USA, to discuss the future of human health and medical care. With the continuous advancement of domestic pharmaceutical and biotechnological capabilities, Chinese pharmaceutical and biotech companies are making increasingly frequent appearances at the JPMorgan Healthcare Conference, and their perspectives are gaining broader recognition and attention in the global market.

In his keynote address, Mr. Zhu Jielun stated, “Fapon Group remains committed to a development path driven by technological innovation, continuously tackling challenges in the life sciences sector and courageously pursuing technological breakthroughs. We actively respond to national policy initiatives promoting early screening, early diagnosis, and precision medicine, while keeping our corporate mission and vision firmly in mind. Upholding our social responsibilities, we are dedicated to contributing innovative strength to the advancement of the industry.”

From the perspective of upstream reagent raw materials for in vitro diagnostics, Fapon Biotech, a subsidiary of Fapon Group, has established major reagent solution platforms for immunoassay, molecular diagnostics, and clinical chemistry diagnostics, underpinned by seven core technology platforms including genetic engineering recombinant technology and recombinant protein expression. The company has also developed a series of core technologies, such as magnetic bead coating technology, enzyme labeling technology, and chemiluminescent labeling technology.

Mr. Zhu Jielun revealed that the raw material products of Fitop Biotechnology are of excellent quality, with specificity and sensitivity indicators of mass-marketed products already reaching industry-leading levels, and possessing a significant price advantage comparable to international brands.

With its raw materials business as the cornerstone, Fapon Biotech pioneered the “Open Platform Ecosystem” model. Based on comprehensive IVD solutions, it provides one-stop open instrument platforms, reagent solutions, and core reagent raw materials. By expanding partnerships with third-party reagent application developers and empowering midstream manufacturers, Fapon Biotech jointly promotes products through distribution channels to reach major medical institutions, thereby benefiting society and achieving mutual growth with its partners.

Mr. Zhu Jielun stated that since its inception, Fapon Group has focused on future human health management needs and medical development trends, concentrating on the frontiers of life sciences and technology. The group is committed to driving industrial development through innovation and building a healthier, more progressive world. Looking ahead, Fapon Group will continue to uphold its mission of “improving human health and advancing human progress,” consistently championing technological innovation in healthcare. By integrating comprehensive ecosystem services with incubation funds, the group aims to provide fertile ground for the growth of enterprises within its ecosystem model.

Regarding future development, Mr. Zhu Jielun pointed out that, drawing from the successful experiences of other major life science enterprises, financial capital investment is also a crucial measure to further accelerate sustainable business growth. While internal incubation through independent development is important, pathways such as collaborative development, investment, and mergers and acquisitions (M&A) are indispensable for fostering innovative businesses. In the future, Fapon Group will steadily enhance the role and significance of its industrial funds and M&A investments in the development of its core businesses.

Currently, Fapon Group is focusing on R&D in the field of precision diagnosis and treatment, deploying an AI-powered multi-omics technology platform to drive innovations in digital pathology, advances in biotherapeutic modalities, and the discovery and application of novel biomarkers, thereby promoting the development of diagnostic and therapeutic technologies. The related technologies and products are expected to be applied across a diverse range of precision medicine scenarios, including precision diagnostics, cell therapy, targeted therapy, early cancer screening, precise disease prediction, therapeutic target development, and precise monitoring of disease progression.

Specifically, in the pharmaceutical sector, Fapon Group actively addresses the global demand for innovation and development in the medical industry. Leveraging multi-omics data—including genomics, transcriptomics, proteomics, metabolomics, and microbiomics—the company continuously identifies cutting-edge, innovative, and efficient potential drug targets for biopharmaceutical companies and R&D institutions. Additionally, it discovers and characterizes novel biomarkers to facilitate the incubation of more precise and efficacious new drugs.

Meanwhile, in the realm of integrated digital diagnostics and treatment, Fapon will introduce AI empowerment and establish a big data analytics platform. By precisely collecting and performing deep learning on clinical data across multi-omics dimensions, and maintaining iterative updates, Fapon aims to guide the advanced development of integrated diagnostics and treatment.

Mr. Zhu Jielun stated that Fapon Group has accelerated its business layout and development through capital investment and financial cooperation. Currently, leveraging its core businesses and competitive advantages, the group has initiated highly targeted investments, mergers, and acquisitions, while globally identifying innovative biomedical enterprises that align with the Fapon ecosystem and the group’s strategic direction. In the future, Fapon Group aims to achieve a new paradigm in which capital empowers industry innovation-driven development.

Whether it is angel incubation investment for early-stage businesses or equity investment for growth-stage businesses, star enterprises in the market are a scarce resource. From the perspective of Fapon Group, it can provide substantial support to its portfolio companies in areas such as product distribution channels, production capacity, customer resources, technological expertise, corporate governance, and strategic planning. This support helps portfolio companies achieve rapid development, which constitutes the core competency of Fapon Group in making successful capital investments.

In his keynote address, Mr. Zhu Jielun emphasized that Fapon Group’s investment philosophy is rooted in the industrial logic of “long-term value,” rather than actively or primarily focusing on short-term value realization. “We aim to grow alongside our portfolio companies, providing ongoing guidance, resources, and support to help them achieve greater success.”